Management ChangeJun 22, 2026, 04:17 PM
Arvinas CMO Noah Berkowitz to Depart July 3
AI Summary
Arvinas, Inc. announced that its Chief Medical Officer, Dr. Noah Berkowitz, will depart from his employment, effective July 3, 2026. The company has begun a search for a replacement. In connection with his departure, Dr. Berkowitz entered into a separation agreement entitling him to severance benefits, including nine months of continued base salary and health coverage premiums, along with accelerated vesting of certain restricted stock units.
Key Highlights
- Dr. Noah Berkowitz, Chief Medical Officer, will depart from Arvinas.
- Departure is effective July 3, 2026.
- Company has initiated a search for a new Chief Medical Officer.
- Separation agreement includes 9 months of base salary continuation.
- Dr. Berkowitz will receive up to 9 months of health coverage premiums.
- Certain restricted stock units (RSUs) granted before May 9, 2027, will have accelerated vesting.
Price Impact
More from ARVN